IRA biosimilar measure intended to boost uptake so far has 'limited' impact: report

IRA biosimilar measure intended to boost uptake so far has 'limited' impact: report

Source: 
Fierce Pharma
snippet: 

It’s been two years since the Inflation Reduction Act (IRA) was passed, and, while the law's Medicare-negotiated price cuts haven’t yet gone into effect, a change surrounding biosimilar reimbursement rates was instated in 2022.